Slc44a2 Deficiency Unveils an IFN‐I–Dependent Feedback Control of pDC Egress
Advanced Science · 2026
DOI: 10.1002/advs.76325 ↗At a glance
Journal article in Advanced Science, 2026. Written by Ruiqun Chen and 11 co-authors. Institution: State Key Laboratory of Membrane Biology, School of Pharmaceutical Sciences, Key Laboratory of Bioorganic Phosphorus Chemistry and Chemical Biology (…. Major MEDLINE topics: Interferon Type I, Dendritic Cells. 109 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Natural Science Foundation of China, the Ministry of Science and Technology of China National Key R&D Programs, Tsinghua University Education Foundation.
Abstract (original language)
Plasmacytoid dendritic cells (pDCs) are a specialized subset of innate immune cells capable of sensing viral nucleic acids and rapidly producing large amounts of type I interferons (IFN‐I). However, excessive IFN‐I production can cause various immunopathogenic conditions. The capacity for IFN‐I production by pDCs is tightly regulated, yet the underlying mechanisms remain incompletely understood. Here, we describe two levels of negative regulatory mechanisms controlling IFN‐I production by pDCs. First, we identified SLC44A2 as a negative regulator of IFN‐I production. Slc44a2 was highly expressed in resting pDCs but significantly downregulated upon activation. Deficiency of Slc44a2 led to excessive IFN‐I production. Mechanistically, SLC44A2 may restrict IFN‐I production by exporting threonine, asparagine, and glutamine, amino acids that we found to be essential for IFN‐I production in pDCs. Second, we uncovered an IFN‐I‐dependent negative feedback mechanism controlling pDC egress. Excessive IFN‐I restrained pDC migration by downregulating CCR2 and CCR5. This feedback was generally observed during viral infections, autoimmune diseases, and in Slc44a2 ‐deficient mice. Taken together, these two regulatory mechanisms are essential for maintaining pDC homeostasis and preventing systemic overactivation of IFN‐I responses.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- State Key Laboratory of Membrane Biology, School of Pharmaceutical Sciences, Key Laboratory of Bioorganic Phosphorus Chemistry and Chemical Biology (Ministry of Education), Tsinghua Medicine, Tsinghua University, Beijin…
- Institute for Immunology, School of Basic Medical Sciences, Tsinghua Medicine, Tsinghua University, Beijing, China.
- Tsinghua-Peking Center for Life Science, Beijing, China.
- Department of Central Laboratory, The First Hospital of Tsinghua University, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing, China.
- Bioinformatics Institute (BII), Agency for Science, Technology and Research (A*STAR), Singapore.
- School of Pharmaceutical Sciences, Tsinghua Medicine, Tsinghua University, Beijing, China.
ORCID profiles: Ligong Chen
Funding
- National Natural Science Foundation of China
- the Ministry of Science and Technology of China National Key R&D Programs
- Tsinghua University Education Foundation
- Handan-Tsinghua University Joint Research Special Fund
- Ministry of Science and Technology of China
- Tsinghua-Peking Center for Life Sciences
Cite
APA
Chen, R., Wu, T., Shi, Z., Verma, R. K., Sheng, L., Tao, L., Yang, M., Wang, Y., Zhang, C., Fan, H., Wu, L., & Chen, L. (2026). Slc44a2 Deficiency Unveils an IFN‐I–Dependent Feedback Control of pDC Egress. Advanced Science. https://doi.org/10.1002/advs.76325
Vancouver
Chen R, Wu T, Shi Z, Verma RK, Sheng L, Tao L, et al. Slc44a2 Deficiency Unveils an IFN‐I–Dependent Feedback Control of pDC Egress. Advanced Science. 2026. doi:10.1002/advs.76325
BibTeX
@article{Chen2026,
author = {Chen, Ruiqun and Wu, Tao and Shi, Zhen and Verma, Ravi Kumar and Sheng, Linlin and Tao, Lei and Yang, Mingming and Wang, Yuchen and Zhang, Conggang and Fan, Hao and Wu, Li and Chen, Ligong},
title = {Slc44a2 Deficiency Unveils an IFN‐I–Dependent Feedback Control of pDC Egress},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.76325}
}
EUVIMED